Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

Antoni Ribas, Reinhard Dummer, Igor Puzanov, Vanderwalde Ari, Robert H.I. Andtbacka, Olivier Michielin, Anthony J. Olszanski, Josep Malvehy, Jonathan Cebon, Eugenio Fernandez, John M. Kirkwood, Thomas F. Gajewski, Lisa Chen, Kevin S. Gorski, Abraham A. Anderson, Scott J. Diede, Michael E. Lassman, Jennifer Gansert, F. Stephen Hodi, Georgina V. Long

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

(Cell 170, 1109–1119.e1–e4; September 7, 2017) It has come to our attention that we inadvertently mislabeled Figure 2 and Figure S3 during the final preparation of this manuscript. In Figure 2, the number of patients in the PD (PD = progressive disease) group should have been N=5, rather than N=4. In the key on Figure S3, the labels for the solid line and the dashed line were reversed. The solid line should be labeled “all median,” and the dashed line should be labeled “tumor median.” We also omitted to state in the legend of Figure S3 that the all median and tumor median for the CR/PR (CR = complete response; PR = partial response) group were the same. Therefore, the dotted line and the solid line for the CR/PR group in Figure S3A were overlapping. These errors have been corrected online, and we apologize for any confusion they may have caused. [Figure presented] [Figure presented]

Original languageEnglish (US)
Pages (from-to)1031-1032
Number of pages2
JournalCell
Volume174
Issue number4
DOIs
StatePublished - Aug 9 2018

Fingerprint

Oncolytic Virotherapy
T-cells
Infiltration
Immunotherapy
T-Lymphocytes
Tumors
Neoplasms
Labels

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Erratum : Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027)). / Ribas, Antoni; Dummer, Reinhard; Puzanov, Igor; Ari, Vanderwalde; Andtbacka, Robert H.I.; Michielin, Olivier; Olszanski, Anthony J.; Malvehy, Josep; Cebon, Jonathan; Fernandez, Eugenio; Kirkwood, John M.; Gajewski, Thomas F.; Chen, Lisa; Gorski, Kevin S.; Anderson, Abraham A.; Diede, Scott J.; Lassman, Michael E.; Gansert, Jennifer; Hodi, F. Stephen; Long, Georgina V.

In: Cell, Vol. 174, No. 4, 09.08.2018, p. 1031-1032.

Research output: Contribution to journalComment/debate

Ribas, A, Dummer, R, Puzanov, I, Ari, V, Andtbacka, RHI, Michielin, O, Olszanski, AJ, Malvehy, J, Cebon, J, Fernandez, E, Kirkwood, JM, Gajewski, TF, Chen, L, Gorski, KS, Anderson, AA, Diede, SJ, Lassman, ME, Gansert, J, Hodi, FS & Long, GV 2018, 'Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))', Cell, vol. 174, no. 4, pp. 1031-1032. https://doi.org/10.1016/j.cell.2018.07.035
Ribas, Antoni ; Dummer, Reinhard ; Puzanov, Igor ; Ari, Vanderwalde ; Andtbacka, Robert H.I. ; Michielin, Olivier ; Olszanski, Anthony J. ; Malvehy, Josep ; Cebon, Jonathan ; Fernandez, Eugenio ; Kirkwood, John M. ; Gajewski, Thomas F. ; Chen, Lisa ; Gorski, Kevin S. ; Anderson, Abraham A. ; Diede, Scott J. ; Lassman, Michael E. ; Gansert, Jennifer ; Hodi, F. Stephen ; Long, Georgina V. / Erratum : Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027)). In: Cell. 2018 ; Vol. 174, No. 4. pp. 1031-1032.
@article{04958d1d5cc14ce38a24a3ac1647f98d,
title = "Erratum: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))",
abstract = "(Cell 170, 1109–1119.e1–e4; September 7, 2017) It has come to our attention that we inadvertently mislabeled Figure 2 and Figure S3 during the final preparation of this manuscript. In Figure 2, the number of patients in the PD (PD = progressive disease) group should have been N=5, rather than N=4. In the key on Figure S3, the labels for the solid line and the dashed line were reversed. The solid line should be labeled “all median,” and the dashed line should be labeled “tumor median.” We also omitted to state in the legend of Figure S3 that the all median and tumor median for the CR/PR (CR = complete response; PR = partial response) group were the same. Therefore, the dotted line and the solid line for the CR/PR group in Figure S3A were overlapping. These errors have been corrected online, and we apologize for any confusion they may have caused. [Figure presented] [Figure presented]",
author = "Antoni Ribas and Reinhard Dummer and Igor Puzanov and Vanderwalde Ari and Andtbacka, {Robert H.I.} and Olivier Michielin and Olszanski, {Anthony J.} and Josep Malvehy and Jonathan Cebon and Eugenio Fernandez and Kirkwood, {John M.} and Gajewski, {Thomas F.} and Lisa Chen and Gorski, {Kevin S.} and Anderson, {Abraham A.} and Diede, {Scott J.} and Lassman, {Michael E.} and Jennifer Gansert and Hodi, {F. Stephen} and Long, {Georgina V.}",
year = "2018",
month = "8",
day = "9",
doi = "10.1016/j.cell.2018.07.035",
language = "English (US)",
volume = "174",
pages = "1031--1032",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Erratum

T2 - Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (Cell (2017) 170(6) (1109–1119.e10) (S0092867417309522) (10.1016/j.cell.2017.08.027))

AU - Ribas, Antoni

AU - Dummer, Reinhard

AU - Puzanov, Igor

AU - Ari, Vanderwalde

AU - Andtbacka, Robert H.I.

AU - Michielin, Olivier

AU - Olszanski, Anthony J.

AU - Malvehy, Josep

AU - Cebon, Jonathan

AU - Fernandez, Eugenio

AU - Kirkwood, John M.

AU - Gajewski, Thomas F.

AU - Chen, Lisa

AU - Gorski, Kevin S.

AU - Anderson, Abraham A.

AU - Diede, Scott J.

AU - Lassman, Michael E.

AU - Gansert, Jennifer

AU - Hodi, F. Stephen

AU - Long, Georgina V.

PY - 2018/8/9

Y1 - 2018/8/9

N2 - (Cell 170, 1109–1119.e1–e4; September 7, 2017) It has come to our attention that we inadvertently mislabeled Figure 2 and Figure S3 during the final preparation of this manuscript. In Figure 2, the number of patients in the PD (PD = progressive disease) group should have been N=5, rather than N=4. In the key on Figure S3, the labels for the solid line and the dashed line were reversed. The solid line should be labeled “all median,” and the dashed line should be labeled “tumor median.” We also omitted to state in the legend of Figure S3 that the all median and tumor median for the CR/PR (CR = complete response; PR = partial response) group were the same. Therefore, the dotted line and the solid line for the CR/PR group in Figure S3A were overlapping. These errors have been corrected online, and we apologize for any confusion they may have caused. [Figure presented] [Figure presented]

AB - (Cell 170, 1109–1119.e1–e4; September 7, 2017) It has come to our attention that we inadvertently mislabeled Figure 2 and Figure S3 during the final preparation of this manuscript. In Figure 2, the number of patients in the PD (PD = progressive disease) group should have been N=5, rather than N=4. In the key on Figure S3, the labels for the solid line and the dashed line were reversed. The solid line should be labeled “all median,” and the dashed line should be labeled “tumor median.” We also omitted to state in the legend of Figure S3 that the all median and tumor median for the CR/PR (CR = complete response; PR = partial response) group were the same. Therefore, the dotted line and the solid line for the CR/PR group in Figure S3A were overlapping. These errors have been corrected online, and we apologize for any confusion they may have caused. [Figure presented] [Figure presented]

UR - http://www.scopus.com/inward/record.url?scp=85050944829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050944829&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2018.07.035

DO - 10.1016/j.cell.2018.07.035

M3 - Comment/debate

AN - SCOPUS:85050944829

VL - 174

SP - 1031

EP - 1032

JO - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -